Heptares Therapeutics reinforces patent protection for the generation of stabilised GPCRs

24-Nov-2009 - United Kingdom

Heptares Therapeutics Ltd announced the grant of a core patent in the UK on its technology for generating stabilised GPCRs (StaRs) and a series of UK patents on specific StaRs and their use in drug screening (GB2456235, GB2456237, GB2456904, GB2456236). These are the first granted patents based on the initial patent families Heptares acquired from the MRC Laboratory of molecular biology (Cambridge, UK) at its incorporation in 2007.

Heptares’ StaR technology enables GPCRs, normally membrane-bound, to be worked on in solution, allowing the use of structure-based drug discovery technologies and the discovery of novel drugs addressing this important set of targets. Heptares is deploying this technology principally to generate small molecule drugs against currently difficult or intractable GPCR targets in several disease areas.

“Through its founding relationship with the MRC, exclusive licensing, careful management of proprietary know-how, and its own in-house GPCR and drug discovery expertise, Heptares has created a well-protected position for its StaR technology platform,” said Malcolm Weir, Heptares’ CEO. “From this position, we are confident we can maximize the commercial potential of our StaR platform as we generate novel proprietary drug leads against selected GPCRs.”

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances